IP Library Granted Patent US 8,778,898
Granted Patent B2
US 8,778,898 · App. 13/897,116 · Granted Jul 15, 2014

Oligomer conjugates of heteropentacyclic nucleosides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,898
App. No.
13/897,116
Granted
Jul 15, 2014
Kind
B2
Abstract

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.

Claims (26)

1. A method of treating influenza, comprising administering to a patient, a compound having the following structure:

wherein:

R 2 is hydrogen or hydroxyl;

R 3 is hydroxyl when R 2 is hydrogen and R 3 is hydrogen when R 2 is hydroxyl;

(a) is two;

X is an amide linkage; and

each POLY is independently a water-soluble, non-peptidic oligomer, and 5′-phosphates and 3′,5′-cyclic phosphates thereof and ammonium and alkali metal salts of each of the 5′-phosphates and 3′,5′-cyclic phosphates.

2. The method of claim 1 , wherein the weight average molecular weight of each water-soluble, non-peptidic oligomer is less than 400 Daltons.

3. The method of claim 1 , wherein each water-soluble, non-peptidic oligomer is a poly(alkylene oxide).

4. The method of claim 3 , wherein each poly(alkylene oxide) is a poly(ethylene oxide).

5. The method of claim 4 , wherein the poly(ethylene oxide) oligomer has a number of repeating monomers in the range of from 1 to 30.

6. The method of claim 5 , wherein the water-soluble, non-peptidic oligomer has a number of repeating monomers in the range of from 1 to 10.

7. The method of claim 3 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

8. The method of claim 1 , wherein the compound is administered as part of a composition comprising (i) the compound of claim 1 , and (ii) a pharmaceutically acceptable excipient.

9. The method of claim 1 , wherein a dosage form comprising the compound of claim 1 is administered.

10. The method of claim 1 , wherein the compound is administered orally.

11. The method of claim 8 , wherein the composition is administered orally.

12. The method of claim 1 , wherein the amount of compound administered is in the range of 0.01 mg to 750 mg.

13. The method of claim 1 , wherein the compound is selected from a compound of the formula

wherein for each occurrence, n is an integer from 1 to 15; and 5′-phosphates and 3′,5′-cyclic phosphates thereof and ammonium and alkali metal salts of each of the 5′-phosphates and 3′,5′-cyclic phosphates.

14. The method of claim 13 , wherein for each occurrence, n is an integer from 1 to 10.

15. The method of claim 14 , wherein for each occurrence, n is 5.

16. The method of claim 13 , wherein the compound is administered as part of a composition comprising (i) the compound of claim 13 , and (ii) a pharmaceutically acceptable excipient.

17. The method of claim 13 , wherein the compound is administered orally.

18. The method of claim 16 , wherein the compound is administered orally.

19. The method of claim 13 , wherein the amount of compound administered is in the range of 0.01 mg to 750 mg.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 31217, FRAME 0776 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036876/0130 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
SECURITY AGREEMENT Recorded Sep 16, 2013
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 031217/0776 →